Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-01-08 Sale | 2024-01-10 4:15 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 2,275 | $28.87 | $65,682 | 43,927 (Direct) | View |
| 2024-01-03 Sale | 2024-01-05 4:50 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 5,532 | $29.46 | $162,973 | 46,202 (Direct) | View |
| 2023-01-04 Sale | 2023-01-06 5:39 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 4,838 | $37.82 | $182,982 | 17,629 (Direct) | View |
| 2022-01-01 Sale | 2022-03-03 8:03 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 1,148 | $112.25 | $128,863 | 42,947 (Direct) | View |
| 2021-08-30 Sale | 2021-09-01 7:34 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 97,000 | $154.83 | $15,018,054 | 164,391 (Direct) | View |
| 2021-08-04 Sale | 2021-08-06 6:19 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 26,000 | $138.24 | $3,594,357 | 111,391 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-01 Option Award | 2024-03-05 4:10 pm | N/A 2034-02-28 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 92,760 | $0 | 136,687 (Direct) | View |
| 2024-01-01 Exercise | 2024-01-03 5:35 pm | 2024-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 3,500 | $0 | 55,234 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-26 4:50 pm | N/A 2033-06-22 | Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director | 36,200 | $0 | 36,200 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 5:14 pm | N/A 2033-02-28 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 72,240 | $0 | 89,869 (Direct) | View |
| 2023-01-01 Exercise | 2023-01-04 8:38 pm | 2023-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 3,500 | $0 | 29,467 (Direct) | View |
| 2022-06-17 Option Award | 2022-06-22 4:41 pm | N/A 2032-06-17 | Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director | 15,500 | $0 | 15,500 (Direct) | View |
| 2022-03-01 Option Award(A) | 2022-03-04 8:58 pm | N/A 2032-02-28 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 20,203 | $0 | 20,203 (Direct) | View |
| 2022-01-01 Exercise | 2022-03-03 8:03 pm | 2022-01-01 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 3,500 | $0 | 42,947 (Direct) | View |
| 2022-03-01 Option Award | 2022-03-03 8:03 pm | N/A 2032-02-28 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 13,816 | $0 | 42,947 (Direct) | View |
| 2021-08-30 Exercise | 2021-09-01 7:34 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 70,000 | $14.25 | 164,391 (Direct) | View |
| 2021-08-30 Exercise | 2021-09-01 7:34 pm | N/A 2030-03-01 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 97,000 | $0 | 164,391 (Direct) | View |
| 2021-08-30 Exercise | 2021-09-01 7:34 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 27,000 | $13.4 | 164,391 (Direct) | View |
| 2021-08-04 Exercise | 2021-08-06 6:19 pm | N/A 2030-03-01 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 26,000 | $0 | 111,391 (Direct) | View |
| 2021-08-04 Exercise | 2021-08-06 6:19 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 26,000 | $13.4 | 111,391 (Direct) | View |
| 2021-06-17 Option Award | 2021-06-21 5:01 pm | N/A 2031-06-17 | Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director | 15,500 | $0 | 15,500 (Direct) | View |
| 2021-03-03 Option Award | 2021-03-05 5:54 pm | N/A 2031-03-02 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 98,000 | $0 | 98,000 (Direct) | View |
| 2020-11-23 Option Award | 2020-11-24 4:42 pm | N/A 2030-11-23 | Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director | 31,000 | $0 | 31,000 (Direct) | View |
| 2020-03-02 Option Award | 2020-03-04 5:30 pm | N/A 2030-03-01 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 135,000 | $0 | 135,000 (Direct) | View |
| 2019-06-03 Option Award | 2019-06-04 4:16 pm | N/A 2029-05-27 | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 150,000 | $0 | 150,000 (Direct) | View |